Eikon Therapeutics, Inc.
EIKN
$8.88
-$0.10-1.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 16.86% | 27.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.35% | 22.41% | |||
| Operating Income | -22.35% | -22.41% | |||
| Income Before Tax | -21.56% | -22.69% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -21.56% | -22.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.56% | -22.69% | |||
| EBIT | -22.35% | -22.41% | |||
| EBITDA | -21.49% | -21.20% | |||
| EPS Basic | 90.85% | -8.37% | |||
| Normalized Basic EPS | 90.01% | -8.10% | |||
| EPS Diluted | 90.85% | -8.37% | |||
| Normalized Diluted EPS | 90.01% | -8.10% | |||
| Average Basic Shares Outstanding | 1,116.45% | 13.21% | |||
| Average Diluted Shares Outstanding | 1,116.45% | 13.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||